Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.73 |
| ▸ | CCNE2 | O96020 | 8/20 | 0.73 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.73 |
| ▸ | CDK1 | P06493 | 2/20 | 0.57 |
| ▸ | CDK5 | Q00535 | 10/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 10/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27562797 | 0.85 | CDK2 (0.77) | CDK2CCNE2CCNE1CDK1CDK5 | |
| SCHEMBL5828199 | 0.85 | CDK2 (1.00) | CDK2CCNE2CCNE1CDK1CDK5 | |
| SCHEMBL5827987 | 0.82 | CDK2 (0.75) | CDK2CCNE2CCNE1CDK1CDK5 | |
| SCHEMBL22587434 | 0.77 | CDK1 (0.71) | CDK2CCNE2CCNE1CDK1CDK5 | |
| SCHEMBL6934104 | 0.76 | CDK5 (0.63) | CDK2CCNE2CCNE1CDK1CDK5 | |
| SCHEMBL5827485 | 0.74 | CDK2 (0.61) | CDK2CCNE2CCNE1CDK1CDK5 | |
| SCHEMBL5827777 | 0.73 | CDK5 (0.79) | CDK2CCNE2CCNE1CDK1CDK5 | |
| SCHEMBL18470737 | 0.72 | CDK5 (0.79) | CDK2CCNE2CCNE1CDK5CDK5R1 | |
| SCHEMBL1394954 | 0.71 | CCNE1 (0.77) | CDK2CCNE2CCNE1CDK1CDK5 | |
| SCHEMBL17212875 | 0.70 | CDK5 (0.78) | CDK2CCNE2CCNE1CDK1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109330-B2 | Purine inhibitors of cyclin dependent kinase 2 and IκB-α | CV THERAPEUTICS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1150982-B1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-alpha | CV THERAPEUTICS INC (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1021186-B1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | LUM ROBERT T (US) | 2005-04-14 | — | — | US | disclosed |
| US-6794390-B2 | TREATING CELL PROLIFERATIVE DISORDERS SUCH AS RHEUMATOID ARTHRITIS, LUPUS, TYPE I DIABETES, MULTIPLE SCLEROSIS, CANCER, RESTENOSIS, HOST GRAFT DISEASE, GOUT, AND POLYCYSTIC KIDNEY DISEASE. | CV THERAPEUTICS, INC. | 2004-09-21 | — | — | US | disclosed |
| US-6790958-B2 | ANTIPROLIFERATIVE AGENTS; FUNGICIDES | LUM ROBERT T (US) | 2004-09-14 | — | — | US | disclosed |
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-20020035252-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkBa | LUM ROBERT T (US) | 2002-03-21 | — | — | US | disclosed |
| US-20020032327-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkappaBalpha | CV THERAPEUTICS, INC. | 2002-03-14 | — | — | US | disclosed |
| EP-1150982-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND I$g(k)-A$g(a) | CV THERAPEUTICS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000044750-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a) | CV THERAPEUTICS, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-1021186-A4 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS INC (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-1021186-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| US-5866702-A | Purine inhibitors of cyclin dependent kinase 2 | CV THERAPEUTICS, INCORPORATION (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998005335-A9 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | — | 1998-05-28 | — | — | WO | disclosed |
| WO-1998005335-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | CV THERAPEUTICS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | IKBKB, NFKB1, CDK4 | CDK2 5/4885CCNE2 65/4885CCNE1 51/4885 |
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | CDK2 1120/4885CCNE2 401/4885CCNE1 596/4885 |
| US-20020032327-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkappaBalpha | CDKN1A, CCNK, CDK1 | CDK2 4/4885CCNE2 132/4885CCNE1 82/4885 |
| US-20020035252-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkBa | AURKB, CDKN1A, IKBKB | CDK2 8/4885CCNE2 202/4885CCNE1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.